Found: 66
Select item for more details and to access through your institution.
BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1632, doi. 10.1002/ajh.27359
- By:
- Publication type:
- Article
Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. E7, doi. 10.1002/ajh.26381
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 46, doi. 10.1002/ajh.25306
- By:
- Publication type:
- Article
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1214, doi. 10.1002/ajh.24887
- By:
- Publication type:
- Article
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 606, doi. 10.1002/ajh.24360
- By:
- Publication type:
- Article
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 11, p. 1060, doi. 10.1002/ajh.24174
- By:
- Publication type:
- Article
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 6, p. 808, doi. 10.1111/ejh.13608
- By:
- Publication type:
- Article
Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 2, p. 197, doi. 10.1111/ejh.13192
- By:
- Publication type:
- Article
Response Dynamics in Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 3, p. 217, doi. 10.3816/CLM.2009.n.043
- By:
- Publication type:
- Article
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 12, p. e2347950, doi. 10.1001/jamanetworkopen.2023.47950
- By:
- Publication type:
- Article
CML-375: AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S334, doi. 10.1016/S2152-2650(21)01782-1
- By:
- Publication type:
- Article
CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S335, doi. 10.1016/S2152-2650(21)01784-5
- By:
- Publication type:
- Article
CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S336, doi. 10.1016/S2152-2650(21)01785-7
- By:
- Publication type:
- Article
CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S334, doi. 10.1016/S2152-2650(21)01781-X
- By:
- Publication type:
- Article
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S328, doi. 10.1016/S2152-2650(21)01769-9
- By:
- Publication type:
- Article
Poster: CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01412-9
- By:
- Publication type:
- Article
Poster: CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01411-7
- By:
- Publication type:
- Article
Poster: CML-375: AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01410-5
- By:
- Publication type:
- Article
Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01409-9
- By:
- Publication type:
- Article
Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01408-7
- By:
- Publication type:
- Article
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01274-X
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.236
- By:
- Publication type:
- Article
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S289, doi. 10.1016/j.clml.2019.07.234
- By:
- Publication type:
- Article
A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S286, doi. 10.1016/j.clml.2019.07.230
- By:
- Publication type:
- Article
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S287, doi. 10.1016/j.clml.2019.07.231
- By:
- Publication type:
- Article
An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S229, doi. 10.1016/j.clml.2018.07.105
- By:
- Publication type:
- Article
Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S223, doi. 10.1016/j.clml.2018.07.094
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S14, doi. 10.1016/j.clml.2017.09.042
- By:
- Publication type:
- Article
CML Management in 2017.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S1, doi. 10.1016/j.clml.2017.08.004
- By:
- Publication type:
- Article
Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S312, doi. 10.1016/j.clml.2017.07.113
- By:
- Publication type:
- Article
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Current Practices in the Management of Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 1, p. 48, doi. 10.1016/j.clml.2012.07.009
- By:
- Publication type:
- Article
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 873, doi. 10.2147/CMAR.S353374
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.234864
- By:
- Publication type:
- Article
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 6247, doi. 10.1007/s00432-022-04562-5
- By:
- Publication type:
- Article